Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients

European Journal of Internal Medicine

Volumn 20, Issue 7, 2009, Pages 712-717

  Tretjakovs, Peteris ^a,b   Jurka, Antra ^a,b   Bormane, Inga ^a   Mackevics, Vitolds ^c   Mikelsone, Indra ^a   Balode, Liga ^a   Reihmane, Dace ^a   Stukena, Inga ^c   Bahs, Guntis ^c   Aivars, Juris Imants ^a   Pirags, Valdis ^b  

^a UNIVERSITY OF LATVIA   (Latvia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^c RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

Adiponectin; Chemokines; Coronary artery disease; Insulin resistance; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-8; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 70349783826     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2009.08.004     Document Type: Article

References (56)

1. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338 (1998) 436-445
2. Gerszten R.E., Mach F., Sauty A., Rosenzweig A., and Luster A.D. Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med 136 (2000) 87-92
3. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 (2005) 2279-2299
4. Charo I.F., and Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 95 (2004) 858-866
5. Herder C., Baumert J., Thorand B., Koenig W., de Jager W., Meisinger C., et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Ausburg study, 1984-2002. Diabetologia 49 (2006) 921-929
6. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 (2003) 1785-1788
7. Shin W.S., Szuba A., and Rockson S.G. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160 (2002) 91-102
8. Bruun J.M., Verdich C., Toubro S., Astrup A., and Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 148 5 (2003) 535-542
9. Haluzik M. Adiponectin and its potential in the treatment of obesity, diabetes and insulin resistance. Curr Opin Investig Drugs. 6 10 (2005) 988-993
10. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102 30 (2005) 10610-10615
11. Bilgili S., Celebiler A.C., Dogan A., and Karaca B. Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients. Endocr Regul 42 2-3 (2008) 63-68
12. Herder C., Hauner H., Haastert B., Röhrig K., Koenig W., Kolb H., et al. Rathmann Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diabetes Care 29 7 (2006) 1626-1631
13. Pineiro R., Iglesias M.J., Gallego R., Raghay K., Eiras S., Rubio J., et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579 23 (2005) 5163-5169
14. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005) 117-121
15. Schaffler A., Scholmerich J., and Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 6 (2005) 273-280
16. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11 10 (2005) 1096-1103
17. Cha S.H., Lee J.K., Lee J.Y., Kim H.T., Ryu H.J., Han B.G., et al. Association of CCR2 polymorphisms with the number of closed coronary artery vessels in coronary artery disease. Clin Chim Acta 382 1-2 (2007) 129-133
18. Ezenwaka C.E., Nwagbara E., Seales D., Okali F., Sell H., and Eckel J. Insulin resistance, leptin and monocyte chemotactic protein-1 levels in diabetic and non-diabetic Afro-Caribbean subjects. Arch Physiol Biochem 115 1 (2009) 22-27
19. Herder C., Haastert B., Müller-Scholze S., Koenig W., Thorand B., Holle R., et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54 Suppl 2 (2005) S11-S17
20. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 9491 (2005) 1059-1062
21. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 1 (2000) 57-63
22. Kouyama K., Miyake K., Zenibayashi M., Hirota Y., Teranishi T., Tamori Y., et al. Association of serum MCP-1 concentration and MCP-1 polymorphism with insulin resistance in Japanese individuals with obese type 2 diabetes. Kobe J Med Sci 53 6 (2008) 345-354
23. Kim C.S., Park H.S., Kawada T., Kim J.H., Lim D., Hubbard N.E., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30 (2006) 1347-1355
24. Herder C., Baumert J., Thorand B., Martin S., Löwel H., Kolb H., et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 26 9 (2006) 2147-2152
25. Sell H., Dietze-Schroeder D., Kaiser U., and Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 147 5 (2006) 2458-2467
26. Sartipy P., and Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100 (2003) 7265-7270
27. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285 (2003) E527-E533
28. Yamauchi T., and Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 32 Suppl 7 (2008) S13-S18
29. de Lemos J.A., Morrow D.A., Sabatine M.S., Murphy S.A., Gibson C.M., Antman E.M., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 5 (2003) 690-695
30. Gonzalez-Quesada C., and Frangogiannis N.G. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep 11 2 (2009) 131-138
31. Charo, I.F., and Taubman, M.B. Chemokines in the pathogenesis of vascular disease. Circ. Res. 95:858-866.
32. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest 116 (2004) 1756-1760
33. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116 1 (2006) 115-124
34. Dahlman I., Kaaman M., Olsson T., Tan G.D., Bickerton A.S., Wåhlén K., et al. A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab 90 10 (2005) 5834-5840
35. Schinner S., Kempf K., Overmann H., Willenberg H.S., Schott M., Rose B., et al. Association of impaired glucose metabolism in morbid obesity with hypoadiponectinaemia. Exp Clin Endocrinol Diabetes 116 Suppl 1 (2008) S64-S69
36. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96 (2000) 34-40
37. Confalonieri P., Bernasconi P., Megna P., Galbiati S., Cornelio F., and Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 59 (2000) 164-169
38. Wisse B.E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15 (2004) 2792-2800
39. Hotamisligil G.S. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 Suppl 3 (2003) S53-S55
40. Bruun J.M., Lihn A.S., Madan A.K., Pedersen S.B., Schiøtt K.M., Fain J.N., et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 286 1 (2004) E8-E13
41. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., Yoshida M., Ding H.A., Gimbrone M.A.J., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398 (1999) 718-723
42. Moreau M., Brocheriou I., Petit L., Ninio E., Chapman M.J., and Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 99 (1999) 420-426
43. Boisvert W.A. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 14 4 (2004) 161-165
44. Anguera I., Miranda-Guardiola F., Bosch X., Filella X., Sitges M., Marin J.L., et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 144 (2004) 811-817
45. Romuk E., Skrzep-Poloczek B., Wojciechowska C., Tomasik A., Birkner E., Wodniecki J., et al. Selectin-P and interleukin-8 plasma levels in coronary heart disease patients. Eur J Clin Invest 32 (2002) 657-661
46. Huber A.R., Kunkel S.L., Todd R.F., and Weiss S.J. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 254 (1991) 99-102
47. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 250 (2001) 91-104
48. Erbagci A.B., Tarakcioglu M., Coskun Y., Sivasli E., and Sibel N.E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem 34 (2001) 645-650
49. Zozulinska D., Majchrzak A., Sobieska M., Wiktorowicz K., and Wierusz-Wysocka B. Serum interleukin-8 level is increased in diabetic patients. Diabetologia 42 (1999) 117-118
50. Straczkowski M., Dzienis-Straczkowska S., Stepien A., Kowalska I., Szelachowska M., and Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 87 (2002) 4602-4606
51. Kissebah A.H., and Krakower G.R. Regional adiposity and morbidity. Physiol Rev 74 (1994) 761-811
52. Despres J.P., Lemieux I., and Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. Br Med J 322 (2001) 716-720
53. Ravussin E., and Smith S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann NY Acad Sci 967 (2002) 363-378
54. Kobashi C., Urakaze M., Kishida M., Kibayashi E., Kobayashi H., Kihara S., et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97 (2005) 1245-1252
55. Touyz R.M. Endothelial cell IL-8, a new target for adiponectin: implications in vascular protection. Circ Res 97 12 (2005) 1216-1219
56. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-767